Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $19000.0.

  • Eton Pharmaceuticals' Other Non-Current Assets rose 5833.33% to $19000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $19000.0, marking a year-over-year increase of 5833.33%. This contributed to the annual value of $12000.0 for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Other Non-Current Assets of $19000.0 as of Q3 2025, which was up 5833.33% from $12000.0 recorded in Q2 2025.
  • Eton Pharmaceuticals' 5-year Other Non-Current Assets high stood at $36000.0 for Q1 2021, and its period low was $12000.0 during Q1 2022.
  • Moreover, its 5-year median value for Other Non-Current Assets was $12000.0 (2022), whereas its average is $15736.8.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first crashed by 7160.49% in 2021, then skyrocketed by 5833.33% in 2025.
  • Eton Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $21000.0 in 2021, then plummeted by 42.86% to $12000.0 in 2022, then changed by 0.0% to $12000.0 in 2023, then changed by 0.0% to $12000.0 in 2024, then soared by 58.33% to $19000.0 in 2025.
  • Its Other Non-Current Assets stands at $19000.0 for Q3 2025, versus $12000.0 for Q2 2025 and $12000.0 for Q1 2025.